“ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.”
Izraely, S., S. Ben-Menachem, O. Sagi-Assif, T. Meshel, D. M. Marzese, S. Ohe, I. Zubrilov, M. Pasmanik-Chor, D. S. B. Hoon and I. P. WitzOncotarget, 2017.
Oncotarget, 2017.
“CCR4 is a determinant of melanoma brain metastasis.”
Klein, A., O. Sagi-Assif, T. Meshel, A. Telerman, S. Izraely, S. Ben-Menachem, J. Bayry, D. M. Marzese, S. Ohe, D. S. B. Hoon, N. Erez and I. P. WitzOncotarget, 2017.
“A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.”
Krepler, C., K. Sproesser, P. Brafford, M. Beqiri, B. Garman, M. Xiao, B. Shannan, A. Watters, M. Perego, G. Zhang, A. Vultur, X. Yin, Q. Liu, I. N. Anastopoulos, B. Wubbenhorst, M. A. Wilson, W. Xu, G. Karakousis, M. Feldman, X. Xu, R. Amaravadi, T. C. Gangadhar, D. E. Elder, L. E. Haydu, J. A. Wargo, M. A. Davies, Y. Lu, G. B. Mills, D. T. Frederick, M. Barzily-Rokni, K. T. Flaherty, D. S. Hoon, M. Guarino, J. J. Bennett, R. W. Ryan, N. J. Petrelli, C. L. Shields, M. Terai, T. Sato, A. E. Aplin, A. Roesch, D. Darr, S. Angus, R. Kumar, E. Halilovic, G. Caponigro, S. Jeay, J. Wuerthner, A. Walter, M. Ocker, M. B. Boxer, L. Schuchter, K. L. Nathanson and M. HerlynCell Rep, 2017.
“Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.”
Leu, J. I., T. Barnoud, G. Zhang, T. Tian, Z. Wei, M. Herlyn, M. E. Murphy and D. L. GeorgeOncotarget, 2017.
“Signaling and Immune Regulation in Melanoma Development and Responses to Therapy.”
Lin, W. M. and D. E. FisherAnnu Rev Pathol, 2017.
“PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.”
Lu, H., S. Liu, G. Zhang, W. Bin, Y. Zhu, D. T. Frederick, Y. Hu, W. Zhong, S. Randell, N. Sadek, W. Zhang, G. Chen, C. Cheng, J. Zeng, L. W. Wu, J. Zhang, X. Liu, W. Xu, C. Krepler, K. Sproesser, M. Xiao, B. Miao, J. Liu, C. D. Song, J. Y. Liu, G. C. Karakousis, L. M. Schuchter, Y. Lu, G. Mills, Y. Cong, J. Chernoff, J. Guo, G. M. Boland, R. J. Sullivan, Z. Wei, J. Field, R. K. Amaravadi, K. T. Flaherty, M. Herlyn, X. Xu and W. GuoNature, 2017.
“A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin.”
Mujahid, N., Y. Liang, R. Murakami, H. G. Choi, A. S. Dobry, J. Wang, Y. Suita, Q. Y. Weng, J. Allouche, L. V. Kemeny, A. L. Hermann, E. M. Roider, N. S. Gray and D. E. FisherCell Rep, 2017.
“ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.”
Ndoye, A., A. Budina-Kolomets, C. H. Kugel, 3rd, M. R. Webster, A. Kaur, R. Behera, V. W. Rebecca, L. Li, P. A. Brafford, Q. Liu, Y. N. V. Gopal, M. A. Davies, G. B. Mills, X. Xu, H. Wu, M. Herlyn, M. C. Nicastri, J. D. Winkler, M. S. Soengas, R. K. Amaravadi, M. E. Murphy and A. T. WeeraratnaCancer Res, 2017.
“Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.”
Oba, J., B. Esmaeli, J. A. Ellerhorst, G. R. Lyons, D. R. Milton, W. L. Wang, M. P. Macedo, A. J. Lazar, E. A. Grimm and C. ChattopadhyayMelanoma Res, 2017.
“Non-Euclidean phasor analysis for quantification of oxidative stress in ex vivo human skin exposed to sun filters using fluorescence lifetime imaging microscopy.”
Osseiran, S., E. M. Roider, H. Wang, Y. Suita, M. Murphy, D. E. Fisher and C. L. EvansJ Biomed Opt, 2017.
“Adoptive cell therapy: past, present and future.”
Cohen, J. E., S. Merims, S. Frank, R. Engelstein, T. Peretz and M. LotemImmunotherapy, 2017.
“Melanoma in 2017: Moving treatments earlier to move further forwards.”
Davies, M. A. and K. T. FlahertyNat Rev Clin Oncol, 2017.
“Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.”
Fallahi-Sichani, M., V. Becker, B. Izar, G. J. Baker, J. R. Lin, S. A. Boswell, P. Shah, A. Rotem, L. A. Garraway and P. K. SorgerMol Syst Biol, 2017.
“Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.”
Faries, M. B., J. F. Thompson, A. J. Cochran, R. H. Andtbacka, N. Mozzillo, J. S. Zager, T. Jahkola, T. L. Bowles, A. Testori, P. D. Beitsch, H. J. Hoekstra, M. Moncrieff, C. Ingvar, M. Wouters, M. S. Sabel, E. A. Levine, D. Agnese, M. Henderson, R. Dummer, C. R. Rossi, R. I. Neves, S. D. Trocha, F. Wright, D. R. Byrd, M. Matter, E. Hsueh, A. MacKenzie-Ross, D. B. Johnson, P. Terheyden, A. C. Berger, T. L. Huston, J. D. Wayne, B. M. Smithers, H. B. Neuman, S. Schneebaum, J. E. Gershenwald, C. E. Ariyan, D. C. Desai, L. Jacobs, K. M. McMasters, A. Gesierich, P. Hersey, S. D. Bines, J. M. Kane, R. J. Barth, G. McKinnon, J. M. Farma, E. Schultz, S. Vidal-Sicart, R. A. Hoefer, J. M. Lewis, R. Scheri, M. C. Kelley, O. E. Nieweg, R. D. Noyes, D. S. B. Hoon, H. J. Wang, D. A. Elashoff and R. M. ElashoffN Engl J Med, 2017.
“Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations.”
Friedman, A. A., Y. Xia, L. Trippa, L. P. Le, V. Igras, D. T. Frederick, J. A. Wargo, K. K. Tanabe, D. P. Lawrence, D. S. Neuberg, K. T. Flaherty and D. FisherClin Cancer Res, 2017.
“Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.”
Garman, B., I. N. Anastopoulos, C. Krepler, P. Brafford, K. Sproesser, Y. Jiang, B. Wubbenhorst, R. Amaravadi, J. Bennett, M. Beqiri, D. Elder, K. T. Flaherty, D. T. Frederick, T. C. Gangadhar, M. Guarino, D. Hoon, G. Karakousis, Q. Liu, N. Mitra, N. J. Petrelli, L. Schuchter, B. Shannan, C. L. Shields, J. Wargo, B. Wenz, M. A. Wilson, M. Xiao, W. Xu, X. Xu, X. Yin, N. R. Zhang, M. A. Davies, M. Herlyn and K. L. NathansonCell Rep, 2017.